Skip to content

Zymeworks ZYME Changes in unrecognized tax benefits

Changes in unrecognized tax benefits at other companies

BioCryst Pharmaceuticals logo
BioCryst PharmaceuticalsBCRX
-$54.25K-161%

Other financials

Income statement

See full
Revenue$2.4M-91.1%
Operating income-$47.1M-84.0%
Net income-$44.2M-95.1%
EPS (diluted)-$0.59-96.7%

Balance sheet

See full
Cash & equivalents$244.3M+221%
Total debt$17.0M-7.7%
Total equity$163.6M-49.7%
Total assets$478.2M+12.4%

Cash flow

See full
Operating cash flow-$45.7M-1,242%
CapEx$216.0K+1,250%
Free cash flow-$45.9M-1,242%

Valuation

See full
Market cap$1.76B+125%
Enterprise value$1.53B+112%
P/S21.6×+13.2×

Profitability

See full
Operating margin-140.4%+7.3pp
Net margin-126.3%+5.0pp
FCF margin-94.8%+15.5pp

Returns & leverage

See full
Return on equity-42%+29.2pp
Debt / equity0.1×0.0×
Current ratio10.8×+6.1×

Where this comes from

Reported directly by Zymeworks in its filing.

Tagged under the XBRL concept us-gaap:IncomeTaxReconciliationTaxContingencies.

The official record: Zymeworks’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →

Ask your AI about Zymeworks's changes in unrecognized tax benefits.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Zymeworks's changes in unrecognized tax benefits?
Zymeworks (ZYME) reported changes in unrecognized tax benefits of $24.25K in Q4 2025.
What does changes in unrecognized tax benefits mean?
Reflects the financial impact of uncertain tax positions, including reserves for potential tax audits or disputes with taxing authorities. It represents the estimated liability for tax positions that may not be sustained upon examination.